Physician profile
August Liam Beisel
NPI 1205513603
$780.92
in general payments reported to CMS, 2019-2025
17 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $33.03 · 2024: $423 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $780.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $157.87 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Janssen Pharmaceuticals, INC | $145.09 | 2024 | Xarelto |
| Glaxosmithkline, LLC. | $60.67 | 2025 | Nucala, Trelegy Ellipta |
| Abbvie INC. | $57.70 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.05 | 2025 | Ofev |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.84 | 2025 | Lifevest |
| Novo Nordisk INC | $37.43 | 2025 | Ozempic |
| Dexcom, INC. | $36.77 | 2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $29.60 | 2024 | Mounjaro |
| Kyowa Kirin, INC. | $29.32 | 2024 | Crysvita |
| Averitas Pharma INC. | $25.58 | 2025 | Qutenza |
| Calliditas Therapeutics US INC. | $24.57 | 2024 | |
| Janssen Biotech, INC. | $20.83 | 2025 | Tremfya |
| Paratek Pharmaceuticals, INC. | $20.80 | 2024 | Nuzyra |
| Alnylam Pharmaceuticals INC. | $17.77 | 2023 | Onpattro |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $15.77 | 2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $15.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw August Beisel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.